Inhibikase Therapeutics, Inc.

NASDAQ
IKT
Stock
Yield per half year: -30.14%
Dividend yield: 0%
Sector: Healthcare

Share chart Inhibikase Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc.

more details
has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Grade

Underestimation
Title Value Grade
P/S 25.18 1
P/BV 0.8124 9
P/E 0 0
EV/EBITDA -0.7235 0
Total: 3.88
Efficiency
Title Value Grade
ROA, % -48.66 0
ROE, % -52 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.0039 10
Total: 9.4
Growth impulse
Title Value Grade
Yield Revenue, % -76.32 0
Yield Ebitda, % 921.04 10
Yield EPS, % -44.73 0
Total: 6
More

Main owners

Institutions Volume Share, %
Armistice Capital, LLC 186 046 3.01
Vanguard Group Inc 87 447 1.42
Blair (William) & Company, L.L.C. 59 375 0.96
Geode Capital Management, LLC 28 692 0.46
Redmond Asset Management, LLC 20 977 0.34
Edgewood Management Llc 16 666 0.27
Renaissance Technologies, LLC 16 122 0.26
State Street Corporation 10 084 0.16
Tower Research Capital LLC (TRC) 2 200 0.04
Morgan Stanley 1 667 0.03

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Milton H. Werner Ph.D. CEO, President & Director 697.96k 1964 (61 year)
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls N/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. CEO of Clintrex Research Corporation & Member of Scientific Advisory Board N/A
Dan Williams Controller N/A
Mr. Garth Lees-Rolfe CPA Chief Financial Officer N/A 1985 (40 years)

About company

Address: United States, Atlanta. GA, 3350 Riverwood Parkway SE - Open in google maps, Open in yandex maps
Website: https://www.inhibikase.com